4//SEC Filing
LUCI DAVID P 4
Accession 0001104659-21-089396
CIK 0001736243other
Filed
Jul 5, 8:00 PM ET
Accepted
Jul 6, 4:06 PM ET
Size
8.7 KB
Accession
0001104659-21-089396
Insider Transaction Report
Form 4
LUCI DAVID P
DirectorPresident and CEO10% Owner
Transactions
- Award
Stock Option
2021-06-29+350,000→ 350,000 totalExercise: $6.26Exp: 2031-06-28→ Common Stock (350,000 underlying) - Award
Stock Option
2021-07-01+500,000→ 500,000 totalExercise: $6.18Exp: 2031-06-30→ Common Stock (500,000 underlying)
Footnotes (2)
- [F1]On June 29, 2021 (the "June Grant Date"), the Reporting Person was granted stock options to purchase 350,000 shares of the Issuer's common stock. 40% of the stock options granted became vested and exercisable on the June Grant Date and 60% of the stock options shall become vested and exercisable as of each monthly anniversary from the June Grant Date, such that all stock options shall be fully vested and exercisable by June 29, 2024. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person.
- [F2]On July 1, 2021 (the "Employment Agreement Grant Date"), the Reporting Person was granted stock options to purchase 500,000 shares of the Issuer's common stock in connection with the Reporting Person's service as the Issuer's President and Chief Executive Officer pursuant to the Reporting Person's employment agreement. 25% of the stock options granted became vested and exercisable on the Employment Agreement Grant Date and 75% of the stock options shall become vested and exercisable as of each monthly anniversary from the Employment Agreement Grant Date, such that all stock options shall be fully vested and exercisable by July 1, 2024.
Documents
Issuer
Acurx Pharmaceuticals, Inc.
CIK 0001736243
Entity typeother
Related Parties
1- filerCIK 0001271123
Filing Metadata
- Form type
- 4
- Filed
- Jul 5, 8:00 PM ET
- Accepted
- Jul 6, 4:06 PM ET
- Size
- 8.7 KB